# Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects

> **NCT02453672** · PHASE1 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 119 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** SB8
- **BIOLOGICAL:** EU sourced Avastin®
- **BIOLOGICAL:** US Sourced Avastin®

## Key facts

- **NCT ID:** NCT02453672
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2019-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02453672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02453672, "Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02453672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*